As the causative agent of acquired immune deficiency syndrome (AIDS), human immunodeficiency virus type 1 (HIV-1) has exerted a formidable challenge to the biomedical research and has become one of the leading causes of death worldwide. Since its discovery at the Institut Pasteur in 1983, a quarter century of scientific efforts has been applied to designing a valid HIV vaccine, yet this object remains unattainable, mainly because of the conspicuous barrier derived from the virus. Since the introduction of combination antiretroviral therapy in 1996, treatment for HIV-1 has improved, which noticeably elevated the therapeutic effect for masses of patients who receive antiretroviral drugs. However, the optimism of antiretroviral treatment is restricted by the current impossibility of viral eradication, the sustained medication with complex regimens, the potential toxic effects, and the prevalence of drug-resistant isolates.
The co-receptor discoveries revealed that HIV-1 enters host cells by binding to a cell-surface molecule, CD4, which serves as the primary receptor and then interacting with co-receptor, either CCR5 or the CXCR4. 1 According to a new classification system based on co-receptor use, HIV-1 isolates are now classified into three major groups: R5 (CCR5-tropic), X4 (CXCR4-tropic), and R5X4 (dual-tropic strains, which use both co-receptors with comparable efficiency). 1 One avenue to development of effective HIV therapies is focusing on a distinct population who seem to be naturally resistant to HIV-1 infection. With the property of a stable CD4 þ T-cell count and no signs of AIDS, a small percentage of HIV-seropositive individuals, termed as long-term non-progressors, were observed. This population generally remains healthy during the infected state for more than 10 years. 2 Meanwhile, there is another group of people, high-risk HIV-exposed seronegative individuals who have been exposed to HIV and remain uninfected. These exposures include unprotected sexual behavior with an HIV-infected person, intravenous drug usage with a definite history of needle sharing, vertical transmission from HIV positive mothers to newborn infants, transfusions of blood or blood products contaminated with HIV, as well as persistent parenteral exposure to HIV-infected blood or body fluids. 2 The innate resistance to HIV, in these individuals, appears related to some genetic factors. Chemokine receptor genetic mutations are among the factors, which influence human susceptibility to HIV-1 invasion and disease progress. It has been shown that homozygosity for a 32-bp deletion (delta32/delta32) in the CCR5 allele results in an inactive CCR5 gene product, truncated CCR5 protein, and consequently confers high resistance against HIV-1 infection.
3,4 A deterministic mathematical model also indicated that prevalence of HIV/AIDS is greater in populations homozygous for CCR5 (wild types) as compared with populations that include people heterozygous or homozygous for CCR5 delta32. 5 There is so far an increasing number of preclinical and clinical studies 6, 7 concerning the possibilities of HIV treatment by stem cell or CD4 þ T-cell-based gene therapy, and these findings have highlighted remarkable progress in this field, in spite of the numerous questions, which remain to be resolved. As most HIV strains utilize the chemokine receptor CCR5 to mediate entry into CD4 þ T cells and populations who lack functional CCR5 have no apparent defects, CCR5 has been one of the major targets for HIV-1 gene therapy. In a recent case report, Hu¨tter et al. 8 transplanted stem cells from a donor who was homozygous for CCR5 delta32 into an HIV-1 positive patient with acute myeloid leukemia. The patient remained without viral rebound for 20 months after transplantation and discontinuation of antiretroviral therapy.
However, the inactivating deletion in CCR5 alone would not be adequate, and the risk reduction is finite because there are other strains of HIV that do not depend on CCR5 for infection. HIV-1 infection in subjects homozygous for CCR5 delta32, although rare, has been increasingly reported, 9 and the CCR5 as target for HIV-1 gene therapy thus seems not to flawless. Therefore, it may be hypothesized that the autologous hematopoietic stem cells (AHSCs) of genetic engineering with homozygosity both of the CCR5 delta32 (or other deletion in CCR5) and of an optimal deletion in the CXCR4 allele, coding non-functional receptors respectively, can be transfused into HIV-infected patients. Theoretically, after differentiation into mature blood cells, these modified stem cells should create another CD4 þ host-cell population that is resistant to all types of HIV-1 variants, including R5, X4, and R5X4 strains.
To verify this postulate, the methods that permit the efficient disruption of a selected gene in the human genome are necessary for designing AHSC. A recent clinical trial applied CCR5-specific zinc-finger nucleases to disrupt the CCR5 gene and retouching patients' own CD4 þ T cells, before re-transfusing these cells into the patient, which introduces novel genetic therapeutics. 6 Moreover, if this strategy is successful, the genes of CXCR4 and CCR5 might be targeted simultaneously with this technology in the future.
Although the deficiency of CXCR4 is likely to exhibit hematopoietic and cardiac defects, and CXCR4 possibly has an important role in fetal cerebellar development, 10 as yet there are no clinical reports about the disadvantages of CXCR4 deficiency. In addition, it is possible that the relevant functions of CXCR4 may partially be compensated by other chemokine receptors, and for this reason, stem cell transplantation of AHSCs with the gene deletion of CXCR4 may not engender apparent cacoethic outcomes. Finally, it should be stressed that the strategy is only a medical postulate, and the potential anti-HIV benefits and adverse effects need to be evaluated cautiously. If this hypothesis is proved to be true, we can obtain a novel antiviral strategy to control and treat HIV-1 infection.
